PreDiabetesNCT05531838
Prediabetes Management
A study testing Fu Lishan instant sense hospital dynamic glucose monitoring system in people with PreDiabetes and Metabolic Management Center, run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.
Trial summary
Systematically screen the high-risk population of diabetes in Xinqiao district to understand the characteristics of early glucose metabolism changes and pancreatic islet function changes in patients with pre diabetes. Read more about this study
- Who is it for?
- Ages 20 to 79 yearsHealthy volunteers can take part
- Conditions the study is for
- PreDiabetes, Metabolic Management Center, Continuous Glucose Monitoring
- What is being tested?
- Fu Lishan instant sense hospital dynamic glucose monitoring system
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 190 participants
- Where
- No sites listed yet
- Study dates
- 17 Oct 2022to 31 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 79 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- IConforms to the pre diabetes in the diagnostic criteria of type 2 diabetes in the Chinese guidelines for the prevention and treatment of type 2 diabetes (version 2020) (only use plasma glucose at 0 minutes in OGTT and 120 minutes after taking glucose);
- Initial screening and diagnosis; ③ without other serious basic diseases; ④ Have complete cognition, reading and writing ability, have a smart phone, can use simple functions, and know how to use wechat; ⑤ Those who voluntarily participate in this study are willing to sign the informed consent form.
Who cannot join
- Those who have been diagnosed with diabetes;
- Patients with severe heart, lung, liver and kidney dysfunction;
- Those with mental disorder, language disorder or senile dementia; ④ Those who can't take care of themselves, are bedridden or have mobility problems; ⑤ Lactating or pregnant women; ⑥ Patients with recent history of surgery, trauma, cardio cerebral and other acute large vessel complications and infectious diseases.
About this study
Official title: A Community Controlled Study of MMC Mode Combined With CGM Therapeutic Monitoring Technology in the Management of Patients With Prediabetes
Systematically screen the high-risk population of diabetes in Xinqiao district to understand the characteristics of early glucose metabolism changes and pancreatic islet function changes in patients with pre diabetes. Relying on MMC platform and combined with CGM therapeutic monitoring technology to standardize the management of patients with prediabetes, it is expected that the annual conversion rate of diabetes in patients with prediabetes will be 8% (according to the literature, if the pre diabetes population is not intervened, the annual conversion rate of diabetes will be about 14%), which will move forward the management of diabetes and create a new mode of pre diabetes management.
Read the detailed description
Part I: Establish the first standardized study cohort of prediabetes patients in Songjiang
On the basis of previous studies, we will continue to carry out early screening of diabetes high-risk groups. It is planned to complete 500 high-risk screening cases in Xinqiao area, and all screened patients will have their medical history and relevant laboratory examinations, and will be followed up regularly. The standard OGTT method was used for screening. The screening contents included: fasting blood glucose and insulin, blood glucose and insulin levels 2 hours after 75g glucose load, and glycosylated hemoglobin levels. In addition to glucose metabolism, other metabolic related diseases such as hematuria routine, liver and kidney function, uric acid, blood lipids, thyroid function, and urine protein / creatinine were also screened. The establishment of the high-quality high-risk screening project in Xinqiao community will establish the first standardized research cohort of diabetes high-risk and pre diabetes patients in Songjiang area, which has very important strategic significance.
Part II: Standardized management and follow-up based on MMC mode combined with CGM therapeutic monitoring technology
For patients with pre diabetes diagnosed by screening, we will rely on MMC mode and CGM technology for standardized management and follow-up. The management mode is mainly embodied in the following forms: ① using CGM Technology (dynamic glucose monitoring system for auxiliary Lishan instant sense hospital), on the basis of the original eating habits of patients, according to the guidelines and the training of MMC center, patients are guided to adjust their eating mode according to the glucose map monitored by the dynamic glucose monitoring system and the log recorded, so as to implement therapeutic monitoring, so as to control the blood glucose level within the target range as far as possible, And record the amount of various foods accordingly, and then maintain the eating mode and amount basically unchanged. ② Offline management. Patient education at least twice a year and hospital follow-up once a year; ③ Issue health instruction manuals, blood glucose monitoring diaries, etc; ④ A full-time wechat management group is established, and full-time intelligent assistants push diet, sports and other guidance every day. Taking the cases of diabetes patients screened in the previous study of the research group as the control, the annual conversion rate of diabetes was observed one year later.
- Being tested
- Fu Lishan instant sense hospital dynamic glucose monitoring system
- Keywords
- prediabetes, continuous glucose monitoring, metabolic management center
- Medical subject headings
- Prediabetic State
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fu Lishan instant sense hospital dynamic glucose monitoring systemDevice
Using CGM Technology (dynamic glucose monitoring system used in Fu Lishan instant sense hospital), on the basis of patients' original eating habits, according to the guidelines and the training of MMC center, patients are guided to adjust their eating patterns according to the glucose map monitored by the dynamic glucose monitoring system.
| Study group | Role | What they receive |
|---|---|---|
| Fu Lishan instant sense hospital dynamic glucose monitoring system | Other | Using CGM Technology (dynamic glucose monitoring system for Fu Lishan instant sense hospital), on the basis of the original eating habits of patients, according to the guidelines and the training of MMC center, patients are guided to adjust the diet model according to the glucose map monitored by the dynamic glucose monitoring system and the log recorded, so as to implement therapeutic monitoring, control the blood glucose level within the target range as far as possible, and record the amount of various foods accordingly, After that, the eating method and amount remained basically unchanged. Receives: Device: Fu Lishan instant sense hospital dynamic glucose monitoring system |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of diabetes
Incidence rate of patients with pre diabetes turning into diabetes after one year of standardized management
Measured: one year
Secondary outcomes (1)
HbA1c increased by 0.5%
HbA1c increased by 0.5%
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2022
- Study start17 Oct 2022 (estimated)
- Primary completion30 Oct 2023 (estimated)
- Study completion31 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PreDiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 190 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Liping Gu, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05531838
- Sponsor's protocol ID
- CTCCR-2021C20
- Status last verified
- Sep 2022
- First submitted
- 4 Sep 2022
- Last updated
- 8 Sep 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Community Controlled Study of MMC Mode Combined With CGM Therapeutic Monitoring Technology in the Management of Patients With Prediabetes
- ClinicalTrials.gov ID
- NCT05531838
- Acronym / sponsor ID
- CTCCR-2021C20
- Keywords
- prediabetes, continuous glucose monitoring, metabolic management center
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 190 participants (estimated)
- Lead sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineUniversity, hospital or other
- Study start
- 17 Oct 2022 (estimated)
- Primary completion
- 30 Oct 2023 (estimated)
- Study completion
- 31 Dec 2023 (estimated)
- First posted
- 8 Sep 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Systematically screen the high-risk population of diabetes in Xinqiao district to understand the characteristics of early glucose metabolism changes and pancreatic islet function changes in patients with pre diabetes. Relying on MMC platform and combined with CGM therapeutic monitoring technology to standardize the management of patients with prediabetes, it is expected that the annual conversion rate of diabetes in patients with prediabetes will be 8% (according to the literature, if the pre diabetes population is not intervened, the annual conversion rate of diabetes will be about 14%), which will move forward the management of diabetes and create a new mode of pre diabetes management.
Detailed description
Part I: Establish the first standardized study cohort of prediabetes patients in Songjiang
On the basis of previous studies, we will continue to carry out early screening of diabetes high-risk groups. It is planned to complete 500 high-risk screening cases in Xinqiao area, and all screened patients will have their medical history and relevant laboratory examinations, and will be followed up regularly. The standard OGTT method was used for screening. The screening contents included: fasting blood glucose and insulin, blood glucose and insulin levels 2 hours after 75g glucose load, and glycosylated hemoglobin levels. In addition to glucose metabolism, other metabolic related diseases such as hematuria routine, liver and kidney function, uric acid, blood lipids, thyroid function, and urine protein / creatinine were also screened. The establishment of the high-quality high-risk screening project in Xinqiao community will establish the first standardized research cohort of diabetes high-risk and pre diabetes patients in Songjiang area, which has very important strategic significance.
Part II: Standardized management and follow-up based on MMC mode combined with CGM therapeutic monitoring technology
For patients with pre diabetes diagnosed by screening, we will rely on MMC mode and CGM technology for standardized management and follow-up. The management mode is mainly embodied in the following forms: ① using CGM Technology (dynamic glucose monitoring system for auxiliary Lishan instant sense hospital), on the basis of the original eating habits of patients, according to the guidelines and the training of MMC center, patients are guided to adjust their eating mode according to the glucose map monitored by the dynamic glucose monitoring system and the log recorded, so as to implement therapeutic monitoring, so as to control the blood glucose level within the target range as far as possible, And record the amount of various foods accordingly, and then maintain the eating mode and amount basically unchanged. ② Offline management. Patient education at least twice a year and hospital follow-up once a year; ③ Issue health instruction manuals, blood glucose monitoring diaries, etc; ④ A full-time wechat management group is established, and full-time intelligent assistants push diet, sports and other guidance every day. Taking the cases of diabetes patients screened in the previous study of the research group as the control, the annual conversion rate of diabetes was observed one year later.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Fu Lishan instant sense hospital dynamic glucose monitoring system | Other | Device: Fu Lishan instant sense hospital dynamic glucose monitoring systemUsing CGM Technology (dynamic glucose monitoring system for Fu Lishan instant sense hospital), on the basis of the original eating habits of patients, according to the guidelines and the training of MMC center, patients are guided to adjust the diet model according to the glucose map monitored by the dynamic glucose monitoring system and the log recorded, so as to implement therapeutic monitoring, control the blood glucose level within the target range as far as possible, and record the amount of various foods accordingly, After that, the eating method and amount remained basically unchanged. |
Who may qualify
- Ages
- 20 to 79 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- IConforms to the pre diabetes in the diagnostic criteria of type 2 diabetes in the Chinese guidelines for the prevention and treatment of type 2 diabetes (version 2020) (only use plasma glucose at 0 minutes in OGTT and 120 minutes after taking glucose);
Key exclusion criteria (3 listed)
- Those who have been diagnosed with diabetes;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fu Lishan instant sense hospital dynamic glucose monitoring systemUsing CGM Technology (dynamic glucose monitoring system used in Fu Lishan instant sense hospital), on the basis of patients' original eating habits, according to the guidelines and the training of MMC center, patients are guided to adjust their eating patterns according to the glucose map monitored by the dynamic glucose monitoring system. | Device | Fu Lishan instant sense hospital dynamic glucose monitoring system |
Primary outcome
Incidence of diabetes
Time frame: one year
Incidence rate of patients with pre diabetes turning into diabetes after one year of standardized management
1 secondary outcome
HbA1c increased by 0.5%
Time frame: one year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2022.
Related trials for PreDiabetes
RecruitingObservational study
AI-Driven Metabolic Cohort in Overweight/Obese Chinese Adults
Overweight and Obesity, Diabetes Mellitus, Type 2
Active, not recruiting
Metabolic and Inflammatory Outcomes of the Ketogenic Diet Comparing Saturated and Unsaturated Fat Sources
PreDiabetes, Diabetes Mellitus, Type 2
Active, not recruitingEarly Phase 1
Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
Prostate Cancer
Not yet recruitingPhase 4
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
MAFLD in Prediabetes and Diabetes
Active, not recruiting
The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Fu Lishan instant sense hospital dynamic glucose monitoring system in people with PreDiabetes and Metabolic Management Center, run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of diabetes (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2022.